BioCryst Pharmaceuticals Inc (BCRX)
7.485
+0.18
(+2.53%)
USD |
NASDAQ |
Nov 21, 16:00
7.485
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Enterprise Value: 1.978B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 1.978B |
| November 19, 2024 | 1.960B |
| November 18, 2024 | 1.928B |
| November 15, 2024 | 1.922B |
| November 14, 2024 | 2.009B |
| November 13, 2024 | 2.049B |
| November 12, 2024 | 2.086B |
| November 11, 2024 | 2.163B |
| November 08, 2024 | 2.078B |
| November 07, 2024 | 2.055B |
| November 06, 2024 | 2.067B |
| November 05, 2024 | 1.927B |
| November 04, 2024 | 1.989B |
| November 01, 2024 | 2.212B |
| October 31, 2024 | 2.125B |
| October 30, 2024 | 2.200B |
| October 29, 2024 | 2.148B |
| October 28, 2024 | 2.154B |
| October 25, 2024 | 2.113B |
| October 24, 2024 | 2.160B |
| October 23, 2024 | 2.135B |
| October 22, 2024 | 2.113B |
| October 21, 2024 | 2.024B |
| October 18, 2024 | 2.044B |
| October 17, 2024 | 2.017B |
| Date | Value |
|---|---|
| October 16, 2024 | 2.034B |
| October 15, 2024 | 2.015B |
| October 14, 2024 | 2.011B |
| October 11, 2024 | 2.005B |
| October 10, 2024 | 1.941B |
| October 09, 2024 | 1.968B |
| October 08, 2024 | 1.957B |
| October 07, 2024 | 2.007B |
| October 04, 2024 | 2.036B |
| October 03, 2024 | 2.003B |
| October 02, 2024 | 1.995B |
| October 01, 2024 | 1.995B |
| September 30, 2024 | 2.040B |
| September 27, 2024 | 2.113B |
| September 26, 2024 | 2.105B |
| September 25, 2024 | 2.098B |
| September 24, 2024 | 2.115B |
| September 23, 2024 | 2.148B |
| September 20, 2024 | 2.214B |
| September 19, 2024 | 2.223B |
| September 18, 2024 | 2.183B |
| September 17, 2024 | 2.175B |
| September 16, 2024 | 2.173B |
| September 13, 2024 | 2.175B |
| September 12, 2024 | 2.140B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
190.35M
Minimum
Mar 18 2020
3.727B
Maximum
Feb 16 2022
1.780B
Average
1.856B
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 8.271M |
| Perspective Therapeutics Inc | 150.86M |
| Protalix BioTherapeutics Inc | 97.03M |
| Electromed Inc | 233.19M |
| Armata Pharmaceuticals Inc | 165.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.03M |
| Revenue (Quarterly) | 117.08M |
| Total Expenses (Quarterly) | 109.39M |
| EPS Diluted (Quarterly) | -0.07 |
| Gross Profit Margin (Quarterly) | 97.24% |
| Profit Margin (Quarterly) | -11.99% |
| Earnings Yield | -8.15% |
| Normalized Earnings Yield | -8.124 |